Media Release – Draft 4 – Positive Opinion

Actelion Ltd (SIX: ATLN) today announced that it has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) seeking approval for selexipag (Uptravi®) for the treatment of patients with pulmonary arterial hypertension (PAH). ................
................

In order to avoid copyright disputes, this page is only a partial summary.